Dustri Online Services

Books: 0	Journals: 2	Articles: 18

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 11/2013 (854-860)

Efficacy of H2 receptor antagonists for prevention of upper gastrointestinal bleeding during dual-antiplatelet therapy

Takeo Yasu¹,²,³, Noriko Sato⁴, Yosuke Kurokawa², Shigeru Saito⁵ and Masaru Shoji³

¹Department of Pharmacy, Shonan Kamakura General Hospital, Kanagawa, ²Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, ³Department of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo, ⁴Department of Pharmacy, Hayama Heart Center, and ⁵Department of Cardiology and Catheterization Laboratory and Heart Center, Shonan Kamakura General Hospital, Kanagawa, Japan
Proton pump inhibitors (PPI) are frequently used to prevent upper gastrointestinal bleeding (UGIB) in patients receiving dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel. However, the concomitant therapy of PPI and DAPT has been associated with a decreased effect of the antiplatelet drugs and an increased risk of major adverse cardiovascular events (MACE). It has been suggested that histamine H2 receptor antagonists (H2RA) can be used as alternatives to PPI to prevent UGIB during DAPT without an increase in the risk of MACE. We tested this hypothesis in a retrospective cohort study including patients without a prior history of upper gastrointestinal events. We examined the incidence of UGIB and MACE in 296 patients treated with H2RA (H2RA group) and 447 patients not treated with H2RA (control group) during DAPT with aspirin and clopidogrel after drug-eluting stent implantation. The patients treated with PPI were excluded. In the 1-year follow-up, UGIB occurred in 2 patients (0.7%) in the H2RA group and 12 (2.7%) in the control group. The incidence of UGIB was significantly different between the two groups (p = 0.049 in log-rank test). MACE occurred in 31 patients (10.5%) in the H2RA group and in 54 patients (12.1%) in the control group, and the incidence was not significantly different (p = 0.447 in logrank test). Thus, H2RA may be effective safe alternatives to PPI during DAPT in patients without a prior history of upper gastrointestinal events.Correspondence to:
Takeo Yasu, MSc
The Research Hospital
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 54 – No. 6/2016 (471-473)

Vincristine-induced paralytic ileus during induction therapy of treatment protocols for acute lymphoblastic leukemia in adult patients

Takeo Yasu¹, Nobuhiro Ohno², Toyotaka Kawamata², and Yosuke Kurokawa¹

¹Department of Pharmacy, and ²Department of Hematology/Oncology, The Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Vincristine (VCR) is an important drug used in the treatment of acute lymphoblastic leukemia (ALL). VCR-induced neurotoxicity can manifest as peripheral neuropathy, constipation, or paralytic ileus. While there are some case reports describing VCR-induced paralytic ileus (VIPI) in pediatric ALL, there are fewer publication on adult ALL patients. Therefore, we retrospectively investigated VIPI during induction therapy of treatment protocols for ALL in 19 adult patients. The incidence of VIPI was 32%. VIPI was significantly increased in patients receiving concomitant itraconazole (ITCZ) (p = 0.04). We recommend avoidance of the combination of VCR and ITCZ.Correspondence to:
Takeo Yasu, PhD
The Research Hospital
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 54 – No. 12/2016 (1009-1011)

The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin’s lymphoma 

Takeo Yasu, Shunsuke Kobayashi, Mai Horii, Yosuke Kurokawa

Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency. The control of serum uric acid level (UA) is important for prevention of TLS. Febuxostat has demonstrated its superiority over allopurinol in decreasing UA level. We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin’s lymphoma (NHL). Mean UA levels were found to significantly decrease (p = 0.003). HU-TLS was prevented in all patients. Thus, febuxostat 10 mg is effective in prevention of HU-TLS. Future study is need to determine whether the incidence of HU-TLS change with dosage of febuxostat. Correspondence to:
Takeo Yasu, PhD 
The Research Hospital
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan 
Email: yasutakeo-tky@ umin.ac.jp

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 55 – No. 10/2017 (807-810)

Hypersensitivity reaction to β-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab 

Takeo Yasu¹, Yoichi Imai², Nobuhiro Ohno², Kaoru Uchimaru³, Yosuke Kurokawa¹, and Arinobu Tojo²

¹Department of Pharmacy, ²Department of Hematology/Oncology,  The Institute of Medical Science, and ³Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences,  Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
Mogamulizumab (MOG) is a humanized anti-CCR4 monoclonal antibody that is highly cytotoxic for adult T-cell leukemia/lymphoma (ATL) cells. Most non-hematological adverse events are cutaneous adverse reactions in ATL patients. We reviewed the medical records of 24 patients with CCR4-positive aggressive ATL who had received MOG treatment. The incidence of MOG-induced cutaneous adverse reactions (MCARs) was 25% (6 patients). Four patients with MCAR had an interesting clinical course, compared with MCARs reported in previous reports. The factors causing MCAR were suspected to be cefepime, cefozopran, and piperacillin/tazobactam. We consider that hypersensitivity reaction to β-lactam antibiotics is involved in a significant proportion of MCARs. Correspondence to:
Takeo Yasu, PhD 
Department of Pharmacy
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
Email:  yasutakeo-tky@ umin.ac.jp

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 56 – No. 11/2018 (551-554)

NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients 

Yohei Iimura¹, Hitoshi Shimomura¹, Takeo Yasu², Keiko Imanaka¹, Ryuichi Ogawa³, Akihiko Ito⁴, Kenichi Suzuki⁵, Gaku Yamaguchi⁶, Norihisa Kawasaki⁶, and Chimori Konaka⁶

¹Department of Pharmacy, International University of Health and Welfare Ichikawa Hospital, Chiba, ²Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, ³Department of Pharmacotherapy, Meiji Pharmaceutical University, ⁴Department of Medicinal Therapy Research, Meiji Pharmaceutical University, ⁵Department of Pharmacotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, and ⁶Department of Respiratory Surgery, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan
Objectives: Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash. Materials and methods: We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model. Results: Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash. Conclusion: NSAIDs may be useful in preventing EGFR-TKI-related skin rash. Correspondence to:
Yohei Iimura, BSc
Department of Pharmacy
International University of Health and
Welfare Ichikawa Hospital
6-1-14 Kounodai, Ichikawa-shi, Chiba 272-0827, Japan 
Email: [email protected]

Abstract

Clinical Nephrology, Vol. 91 – No. 6/2019 – Letters to the editor

Acute kidney injury incidence in patients with hematological malignancy treated with meropenem and vancomycin for febrile neutropenia

Shunsuke Kobayashi, Takeo Yasu, and Kenji Momo

Department of Pharmacy, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan
Correspondence to:
Shunsuke Kobayashi, MSc
Department of Pharmacy
The Institute of Medical Science Hospital
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku,
Tokyo, 108-8639, Japan
Email: [email protected]

Abstract

Clinical Nephrology, Vol. 92 – No. 2/2019 – Letters to the editor

AKI in patients with hematological malignancies treated with various vancomycin-antibiotic combinations

Shunsuke Kobayashi¹#²*, Takeo Yasu¹#³*, and Kenji Momo¹#⁴

¹Department of Pharmacy, The Institute of Medical Science Hospital, The University of Tokyo, ²Department of Pharmacy, Nissan Tamagawa Hospital, ³Department of Medicinal Therapy Research, Meiji Pharmaceutical University, and ⁴Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan

*Contributed equally
Correspondence to:
Shunsuke Kobayashi, MSc
Department of Pharmacy, Nissan Tamagawa Hospital
4-8-1, Seta, Setagaya-ku, Tokyo,158-0095, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 57 – No. 8/2019 (416-419)

Thiamine deficiency as a possible cofactor causing cognitive dysfunction in a patient with end-stage gastric cancer 

Yohei Iimura¹, Takeo Yasu¹#², Kenji Momo¹#³, Seiichiro Kuroda¹, Yoshiaki Kanemoto⁴, Kentaro Yazawa⁴, and Giichiro Tsurita⁴

¹Department of Pharmacy, Research Hospital, ²Department of Medicinal Therapy Research, Meiji Pharmaceutical University, ³Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, and ⁴Department of Surgery, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan
We describe a case of a patient treated for cognitive dysfunction (CD) with suspected thiamine deficiency (TD). A 74-year-old man with gastric cancer presented with grade 3 diarrhea and grade 1 anorexia. He had been receiving trastuzumab plus tegafur (a chemotherapeutic fluorouracil prodrug), gimeracil, and oteracil (S-1) and oxaliplatin. On admission, cognitive function was assessed with the Hasegawa’s Dementia Scale (HDS-R) because he had impaired short-term memory. His thiamine levels increased from 22 to 109 ng/mL after administration of 75 mg of thiamine. Furthermore, the patient’s HDS-R score improved from 9 to 22, and cognitive and memory functions improved. TD should be considered in older CD patients receiving oral chemotherapy agents including fluorouracil.Correspondence to:
 Yohei Iimura, Bsc. 
Department of Pharmacy, The Research Hospital
The Institute  of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 58 – No. 3/2020 (174-176)

Potential thiamine deficiency in elderly patients with gastrointestinal cancer undergoing chemotherapy 

Takeo Yasu¹#², Yohei Iimura¹, Kenji Momo¹#³, and Seiichiro Kuroda¹

¹Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, ²Department of Medicinal Therapy Research, Meiji Pharmaceutical University, and ³Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan
Gastrointestinal cancer and its treatment using fluorouracil-based anticancer agents are risk factors for thiamine deficiency (TD). Therefore, we aimed to determine the prevalence of TD among elderly patients with gastrointestinal cancer undergoing chemotherapy. We retrospectively reviewed the medical records of 12 elderly patients with gastrointestinal cancers who underwent chemotherapy. Median serum thiamine level was 22.5 ng/mL (range, 17 – 42 ng/mL). Four patients (33.3%) exhibited TD (< 20 ng/mL). We found that the prevalence of TD among elderly patients with gastrointestinal cancer undergoing chemotherapy was high. For these patients, careful monitoring of thiamine levels is warranted because TD may not produce overt clinical symptoms.Correspondence to:
 Takeo Yasu, PhD 
Department of Medicinal Therapy Research
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan
Email: yasutakeo-tky@ umin.ac.jp

Abstract

Clinical Nephrology, Vol. 95 – No. 5/2021 – Letters to the editor

Renally inappropriate medications in elderly patients with chronic kidney disease

Takeo Yasu¹, Daisuke Hayashi², Masatoshi Saitoh³, Yoshiki Yashiro⁴, and Mikio Shirota⁵

¹Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, ²Section of Pharmaceutical Services, Nippon Medical School Hospital Tokyo, ³Department of Pharmacy, Kitasato University Kitasato Institute Hospital Tokyo, Tokyo, ⁴Department of Pharmacy, Yokohama Rosai Hospital, Kanagawa, and ⁵Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan
Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Pharmaceutical Education and Research Center
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 59 – No. 9/2021 (627-629)

Efficacy and safety of tedizolid in a patient with linezolid-induced neutropenia: A case report 

Shunsuke Kobayashi¹, Masanori Kase², Masaaki Matsubara², Akira Kitaoka¹, and Takeo Yasu³

¹Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo, ²Department of Orthopedic Surgery, Nissan Tamagawa Hospital, Tokyo, and ³Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan
Linezolid is used to treat prosthetic joint infection after total hip arthroplasty. Here, we present a case of linezolid-induced severe neutropenia, which improved after switching to tedizolid. Grade 3 neutropenia developed 5 days after linezolid injection (1,200 mg/day) and 33 days after oral administration of the same dose. However, during the 70 days of treatment with tedizolid, grade 3 neutropenia did not occur, and C-reactive protein levels remained in the normal range. No grade ≥ 1 thrombocytopenia or bleeding event occurred during the course of tedizolid treatment. Tedizolid may be an alternative drug for patients who develop linezolid-induced neutropenia. Correspondence to:
 Shunsuke Kobayashi, MSc 
Department of  Pharmacy
Nissan Tamagawa Hospital
4-8-1, Seta, Setagaya-ku, Tokyo 158-0095, Japan
Email: shunsukekobayashi0412 @gmail.com

Abstract

Clinical Nephrology, Vol. 98 – No. 6/2022 (301-304)

Pharmacokinetics of ibrutinib in a patient with chronic lymphocytic leukemia on hemodialysis 

Toyoji Ohtani¹, Akiko Tani¹, Yuki Namme¹, Rie Namme¹, Maki Hirose¹, Ikuo Shingu¹, Yusuke Kizawa², Akira Endo², and Takeo Yasu³

¹Department of Pharmacy, ²Department of Hematology, Matsue Red Cross Hospital, Shimane, and ³Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan
Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, is a key drug for the treatment of chronic lymphocytic leukemia (CLL). It is primarily metabolized by cytochrome P450 3A. However, there are no data on the pharmacokinetics of ibrutinib in patients with severe renal impairment or on hemodialysis (HD). We evaluated the pharmacokinetics of ibrutinib in a patient with CLL undergoing HD. An 84-year-old man on HD was diagnosed with CLL and was started on ibrutinib 140 mg daily. The second day of ibrutinib administration was an HD day, and its plasma concentrations before and 1, 2, 4, and 24 hours after administration were measured and found to be 0, 6.9, 28.4, 57.1, and 0 ng/mL, respectively. The maximum plasma concentration (C_max) and time taken to reach C_max (t_max) on days 14 and 15 of ibrutinib treatment were 64.8 ng/mL (4 hours) and 48.1 ng/mL (2 hours), respectively. Thus, we concluded that HD did not have a significant effect on the pharmacokinetics of ibrutinib in this patient. Therefore, dose adjustment of ibrutinib between HD and non-HD days is not recommended. Interestingly, we found that t_max of the drug was prolonged, and C_max was higher on HD days compared to those on non-HD days.Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Pharmaceutical Education and Research Center
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan
Email: [email protected]

Abstract

Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 61 – No. 2/2023 – Letter to the editor

Atovaquone-induced thrombocytopenia: A case report

Eri Hikita¹, Takeo Yasu¹#², Satoshi Chiyounabayashi³, and Mikio Shirota¹

¹Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, ²Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, and ³Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan
Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Pharmaceutical Education and Research Center
Meiji Pharmaceutical University
2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 61 – No. 7/2023 (315-319)

Effect of infusion time of intravenous acetaminophen on blood pressure in the intensive care unit 

Yasunori Urayama¹, Satoshi Kosaka¹, Tsugumi Ide¹, Mikio Shirota¹#³, and Takeo Yasu¹#²#³

¹Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida-ku, ²Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Noshio, Kiyose, and ³Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Kotobashi, Sumida-ku, Tokyo, Japan
Objective: To understand the effect of prolonged intravenous acetaminophen infusion on blood pressure.
Materials and methods: We retrospectively studied a cohort of intensive care patients receiving initial intravenous acetaminophen. We used propensity score matching to adjust for differences between patients who were classified into two groups: control (acetaminophen infusion for 15 minutes) and prolonged administration (acetaminophen infusion for > 15 minutes).
Results: After acetaminophen administration, diastolic blood pressure was unchanged in the control group, and was significantly lower at 30 and 60 minutes in the prolonged administration group.
Conclusion: Prolonged duration of acetaminophen infusion did not prevent acetaminophen-induced blood pressure reduction.Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Pharmaceutical Education and Research Center
Meiji Pharmaceutical University
2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan
Email: [email protected]

Abstract

Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 61 – No. 8/2023 – Letter to the editor

Dexamethasone-induced hiccups in patients with COVID-19

Tomomi Yagi¹, Takeo Yasu², Sumi Tsubuku³, Hiroyuki Jinnai³, Kenta Otsuka⁴, Shin Takahashi¹, and Takeshi Hagino⁵

¹Department of Pharmacy, Tokyo Metropolitan Tama-Hokubu Medical Center, ²Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, ³Department of Pharmacy, Tokyo Metropolitan Ebara Hospital, ⁴Department of Pharmacy, Tokyo Metropolitan Ohkubo Hospital, and ⁵Department of Hematology, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan
Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Pharmaceutical Education and Research Center
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
Email: [email protected]

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 62 – No. 1/2024 (56-60)

Monitoring of blood levels in patients administered CYP3A4 inhibitor during the maintenance phase of venetoclax administration 

Toshiki Kubo¹, Shunsuke Matsuo¹, Rintaro Sogawa¹, Takeo Yasu², Toshiaki Nagaie³, Sho Okamoto³, Shinya Kimura³, and Chisato Shimanoe¹

¹Department of Pharmacy, Saga University Hospital, Saga, ²Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, and ³Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Objective: Venetoclax, an oral B-cell lymphoma-2 inhibitor, necessitates dose adjustment when combined with a CYP3A4 inhibitor; however, the dosing regimen remains unclear on adding a CYP3A4 inhibitor after venetoclax administration.
Case summary: We present a case report of a patient who was simultaneously treated with a CYP3A4 inhibitor and a steady daily dose of venetoclax. A 30-year-old male diagnosed with acute myeloid leukemia received a combination of venetoclax and azacitidine as remission induction therapy. He was prescribed 400 mg/day venetoclax at a steady daily dose, with fosfluconazole initiated on day 18. Given that fosfluconazole can induce moderate CYP3A4 inhibitory effects, the venetoclax dosage was reduced to 200 mg/day on the same day. Despite dose reduction, plasma trough levels of venetoclax continued rising gradually. Nearly 10 days were required to decrease blood levels to a steady state.
Conclusion: The risk of elevated venetoclax blood levels needs to be considered when initiating CYP3A4 inhibitors and reducing venetoclax dosage on the same day.Correspondence to:
Shunsuke Matsuo, PhD
Department of Pharmacy
Saga University Hospital
5-1-1 Nabeshima
Saga 849-8501, Japan
Email: [email protected]

Abstract

Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 62 – No. 12/2024 – Letter to the editor

Voriconazole trough levels after switching from an intravenous to oral formulation in a patient with short bowel syndrome

Rumi Ishida¹, Takeo Yasu¹#²#³, Mieko Hayakawa¹, and Yoshiyasu Terayama¹

¹Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, ²Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, and ³Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan
Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Education and Research Unit for Comprehensive,
Clinical Pharmacy, Meiji Pharmaceutical University
2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan
Email: [email protected]

Abstract

Intern. Journal of Clinical Pharmacology and Therapeutics, Vol. 63 – No. 8/2025 – Letter to the editor

Selpercatinib blood trough concentration after gastrectomy with RET fusionpositive thyroid cancer: A case report

Naoya Tonomura¹, Takeo Yasu¹#², Chisato Doi¹, Satoshi Yamaguchi¹, and Ayumi Mori³

¹Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, ²Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, and ³Department of Otolaryngology-Head and Neck Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Correspondence to:
Takeo Yasu, PhD
Department of Medicinal Therapy Research
Education and Research Unit for
Comprehensive Clinical Pharmacy
Meiji Pharmaceutical University
2-522-1, Noshio, Kiyose
Tokyo 204-8588, Japan
Email: [email protected]

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail